Spots Global Cancer Trial Database for akt
Every month we try and update this database with for akt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01466868 | Diffuse Large B... | MK2206 | 18 Years - 90 Years | Centre Leon Berard | |
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693 | NCT00493818 | Cancer | GSK690693 | 18 Years - | GlaxoSmithKline | |
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer | NCT00342836 | AKT | Akt levels | 40 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies | NCT03317366 | Proteus Syndrom... PIK3CA-Related ... Growth Disorder... | ARQ 092 | 2 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer | NCT00342836 | AKT | Akt levels | 40 Years - 74 Years | National Institutes of Health Clinical Center (CC) |